Company: 

Synairgen

Synairgen plc

Synairgen used Niche's expertise in the writing of manuscripts to quickly and efficiently develop high-quality documents for submission to relevant journals. Niche's high standards of manuscript preparation and ability to adapt to different journal requirements ensured successful publication. Services included:

  • General editorial and medical writing support
  • Drafting key manuscripts
  • Guiding the team on dissemination strategy
What our client said

"We thank Niche for the enormous contribution they made to moving the Synairgen interferon beta treatment for COVID-19 forwards. We recognise and hugely appreciate the tenacity, adaptiveness dexterity and sheer hard work."

photophotophotophotophoto

Richard Marsden, CEO

Synairgen plc




Project background
Synairgen is a clinical-stage biopharmaceutical company based in the UK, focused on developing novel treatments for respiratory diseases. Founded as a spin-out from the University of Southampton in 2003, the company leverages its expertise in respiratory science and drug development to address unmet medical needs, particularly in conditions like asthma and chronic obstructive pulmonary disease. Synairgen's lead product, SNG001, is an inhaled formulation of interferon beta, aimed at treating viral respiratory infections, including COVID-19. The company has garnered attention for its innovative approach to leveraging existing antiviral therapies to improve patient outcomes in respiratory illnesses. With a commitment to advancing research and development in respiratory health, Synairgen continues to explore new avenues for therapeutic interventions.
Delivery

Niche was approached by Synairgen for support in their interferon beta treatment (SNG001) for COVID-19 and COPD during the pandemic. Niche provided support in the development of manuscripts and regulatory documentation for the Phase II data in COVID-19 and COPD, the revolutionary approach to dosing in the home environment and the initiation of a Phase III trial. The Niche team’s expertise in quick and efficient manuscript writing helped Synairgen stay at the forefront of the wave of treating COVID-19.

Niche's work helped Synairgen get recognised by investors worldwide, which at the time, led to the largest fund raising drive ever experienced by the company. This allowed Synairgen the best opportunity to continue testing their product in further clinical trials. Based on the successful Phase II trial with SNG001 for which Niche contributed massively, Synairgen has since been able to initiate a Phase III trial in 17 countries.

Related Case studies

Medical writing

QC review of an IB update for uzatresgene autoleucel, one of Adaptimmune’s TCR-based therapies.

Niche delivered rigorous QC and medical writing support across Adaptimmune's full suite of regulatory documents, keeping.

read more
Medical writing

BSH is the UK’s largest haematology organisation, promoting excellence within the field and supporting professional development.

Over a decade and 20+ guidelines later, Niche remains the BSH's trusted partner for raising haematology care standards.

read more
Medical writing

The FRAILOMIC initiative was an international research project

Niche built and coordinated the full communications strategy for this 20-institution European initiative, turning.

read more
Medical writing

Nabriva Therapeutics is committed to developing new antibiotics to treat infectious diseases.

Niche supported Nabriva's antibiotic lefamulin from early clinical protocols all the way to FDA, EMA and Health Canada.

read more
Medical writing

Cleothena Enterprises Pty Ltd. is a forward-thinking biotechnology company focused on advancing innovative therapeutic solutions.

When stalled regulatory documentation threatened to derail their neurological programme, Cleothena turned to Niche —.

read more
Medical writing

A specialist pharmaceutical company dedicated to HIV medicines and research with an extensive portfolio of prescription medicines.

Putting patients first, Niche supported ViiV Healthcare's global HIV outreach programmes with medical writing,.

read more
Medical writing

Specialising in the discovery and development of small-molecule drugs for oncology and central nervous system disorders.

Niche provided Astex with expert regulatory writing across their oncology pipeline, delivering clinical protocols, study.

read more
Medical writing

Partnership with a clinical research organisation specialising in comprehensive data services for clinical trials.

For over a decade, Assign DMB relied on Niche as their embedded writing partner, seamlessly converting statistical.

read more
Medical writing

Providing regulatory and medical writing support to meet client needs

Niche served as the English-language regulatory writing backbone for this Nordic consultancy, producing IBs, IMPDs and.

read more

Get our latest news and publications

Sign up to our news letter

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility